Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC

被引：0

作者：

Deininger, Michael

Apperley, Jane

Arthur, Christopher Kevin

Chuah, Charles

Hochhaus, Andreas

de Lavallade, Hugues

Lipton, Jeffrey Howard

Lomaia, Elza

McCloskey, James K.

Maness, Lori J.

Mauro, Michael J.

Moiraghi, Beatriz

Pavlovsky, Carolina

Rosti, Gianantonio

Rousselot, Philippe

Sutton, Maria Undurraga

Ren, Xiaowei

Vorog, Alexander

Kantarjian, Hagop M.

Cortes, Jorge E.

机构：

[1] Versiti Blood Res Inst, Milwaukee, WI USA

[2] Imperial Coll London, London, England

[3] Royal North Shore Hosp, St Leonards, NSW, Australia

[4] Duke NUS Med Sch, Singapore Gen Hosp, Singapore, Singapore

[5] Univ Klinikum Jena, Jena, Germany

[6] Kings Coll Hosp NHS Fdn, London, England

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Almazov Natl Med Res Ctr, St Petersburg, Russia

[9] Hackensack Meridian Hlth, John Theurer Canc Ctr, Hackensack, NJ USA

[10] Univ Nebraska Med Ctr, Omaha, NE USA

[11] Mem Sloan Kettering, New York, NY USA

[12] Hosp Jose Maria Ramos Mejia, Buenos Aires, DF, Argentina

[13] Fundaleu, Buenos Aires, DF, Argentina

[14] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Meldola, FC, Italy

[15] Ctr Hosp Versailles Univ Versailles St Quentin En, Paris, France

[16] Hosp Salvador, Santiago, Chile

[17] Takeda Dev Ctr Amer Inc, Lexington, MA USA

[18] City Hope Natl Med Ctr, Duarte, CA USA

[19] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6501

引用

页数：1

共 50 条

[21] Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)
Mauro, Michael
Gambacorti-Passerini, Carlo
Goldberg, Stuart L.
Cortes, Jorge E.
Khoury, H. Jean
Michallet, Mauricette
Paquette, Ronald
Simonsson, Bengt
Turner, Michelle P.
Mohamed, Hesham
Subar, Milayna
Zyczynski, Teresa
BLOOD, 2014, 124 (21)
[22] Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
Liu, Delong
Matloub, Yousif
Mulchopadhyay, Jaydip
Liu, David
Goldberg, Stuart L.
BLOOD, 2008, 112 (11) : 741 - 741
[23] COMPARISON OF PACE CLINICAL TRIAL VS REAL-WORLD PONATINIB PRESCRIBING AND DURATION OF THERAPY IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS
Mauro, M.
McGarry, L. J.
Yang, M.
Lustgarten, S.
Huang, H.
HAEMATOLOGICA, 2016, 101 : 458 - 458
[24] Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial
Hughes, Timothy P.
Cortes, Jorge E.
Rea, Delphine
Mauro, Michael J.
Hochhaus, Andreas
Kim, Dong-Wook
Sasaki, Koji
Lang, Fabian
Heinrich, Michael C.
Breccia, Massimo
Deininger, Michael
Goh, Yeow-Tee
Janssen, Jeroen J. W. M.
Talpaz, Moshe
le Coutre, Philipp
Kapoor, Shruti
Cacciatore, Silvia
Polydoros, Fotis
Agrawal, Nithya
Mahon, Francois-Xavier
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S300 - S300
[25] Two-year monitoring and treatment patterns in German patients with chronic-phase Chronic Myeloid Leukemia (CP-CML) in a prospective observational study
Tesch, H.
Nusch, A.
Linde, H.
Sen, G. P.
Schollmeyer, A.
Hehlmann, R.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 178 - 179
[26] Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
Lipton, Jeffrey H.
Chuah, Charles
Guerci-Bresler, Agnes
Rosti, Gianantonio
Simpson, David
Assouline, Sarit
Etienne, Gabriel
Nicolini, Franck E.
Le Coutre, Philipp
Clark, Richard
Stenke, Leif
Andorsky, David
Oehler, Vivian
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Haluska, Frank G.
Baccarani, Michele
Cortes, Jorge E.
Guilhot, Francois
Hochhaus, Andreas
Hughes, Timothy P.
Kantarjian, Hagop M.
Shah, Neil P.
Talpaz, Moshe
Deininger, Michael W.
BLOOD, 2014, 124 (21)
[27] Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
Kantarjian, Hagop M.
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil P.
BLOOD, 2013, 122 (21)
[28] AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T315I Mutations
Levy, Moshe Y.
Mauro, Michael J.
Issa, Ghayas C.
Andorsky, David
Tomassetti, Sarah
Maegawa, Rodrigo
Shrestha, Alok
Deininger, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S334 - S335
[29] The Clinical Characteristics and Efficacy of Chronic Myeloid Leukemia Patients with T315I Mutation
Chen Chen
Na Xu
Wu WanEr
Liu Liang
Xuan Zhou
Huang JiXian
Yin Changxin
Rui Cao
Liu, Qifa
Liu Xiaoli
BLOOD, 2018, 132
[30] Cytogenetic and molecular responses in German patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY)
Repp, R.
Hehlmann, R.
Linde, H.
Reiser, M.
Tesch, H.
Foreman, A.
Schreiner, L.
Hillig, G.
Oncology Research and Treatment, 2015, 38 : 132 - 132

← 1 2 3 4 5 →